相似文献
1
The economics of cardiac failure.
J R Soc Med. 1996 Jan;89(1):9-12. doi: 10.1177/014107689608900104.
2
Cost effectiveness of carvedilol for heart failure.
Am J Cardiol. 1999 Mar 15;83(6):890-6. doi: 10.1016/s0002-9149(98)01066-2.
3
Clinical and economic impact of nesiritide.
Am J Health Syst Pharm. 2003 Aug 15;60 Suppl 4:S21-6. doi: 10.1093/ajhp/60.suppl_4.S21.
4
Sodium Nitrite-Mediated Cardioprotection in Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction: A Cost-Effectiveness Analysis.
J Cardiovasc Pharmacol Ther. 2019 Mar;24(2):113-119. doi: 10.1177/1074248418784940. Epub 2018 Aug 6.
5
Nesiritide utilization evaluation in a university teaching hospital.
J Clin Pharm Ther. 2005 Oct;30(5):447-53. doi: 10.1111/j.1365-2710.2005.00665.x.
6
New technologies and potential cost savings related to morbidity and mortality reduction in Class III/IV heart failure patients in Canada.
Int J Cardiol. 2003 Mar;88(1):33-41. doi: 10.1016/s0167-5273(02)00378-9.
7
[Economic significance of heart failure. An overview of costs and economics of therapy].
Herz. 2000 Aug;25(5):538-46. doi: 10.1007/pl00001966.
8
Cost-effective management of heart failure.
Clin Cardiol. 1996 Mar;19(3):240-2. doi: 10.1002/clc.4960190319.
9
Clinical and economic impact of multipoint left ventricular pacing: A comparative analysis from the Italian registry on multipoint pacing in cardiac resynchronization therapy (IRON-MPP).
J Cardiovasc Electrophysiol. 2020 May;31(5):1166-1174. doi: 10.1111/jce.14433. Epub 2020 Mar 12.
10
Health economics of cardiac resynchronization therapy.
Br J Hosp Med (Lond). 2017 Oct 2;78(10):594. doi: 10.12968/hmed.2017.78.10.594.
引用本文的文献
1
The economics of TRACE. A cost-effectiveness analysis of trandolapril in postinfarction patients with left ventricular dysfunction.
Pharmacoeconomics. 1998 Jul;14(1):49-58. doi: 10.2165/00019053-199814010-00005.
2
Culture and medicine.
J R Soc Med. 1998 Mar;91(3):118-26. doi: 10.1177/014107689809100302.
本文引用的文献
1
Effects of ACE inhibitors on heart failure in The Netherlands: a pharmacoeconomic model.
Pharmacoeconomics. 1993 May;3(5):387-97. doi: 10.2165/00019053-199303050-00006.
2
A medication discharge planning program: measuring the effect on readmissions.
Clin Nurs Res. 1993 Feb;2(1):41-53. doi: 10.1177/105477389300200105.
3
Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group.
J Am Coll Cardiol. 1993 Oct;22(4):955-62. doi: 10.1016/0735-1097(93)90403-n.
4
The incidence and prevalence of congestive heart failure in Rochester, Minnesota.
Mayo Clin Proc. 1993 Dec;68(12):1143-50. doi: 10.1016/s0025-6196(12)60063-9.
5
[Increase in the number of admissions due to heart failure in Dutch hospitals in the period 1980-1992].
Ned Tijdschr Geneeskd. 1994 Apr 23;138(17):866-71.
6
Improving patient care: consequences for resource allocation.
Cardiology. 1994;84(6):420-6. doi: 10.1159/000176434.
7
The cost:benefit ratio of acute intervention for myocardial infarction: results of a prospective, matched pair analysis.
Am Heart J. 1989 Nov;118(5 Pt 1):878-82. doi: 10.1016/0002-8703(89)90217-2.
8
Hospital costs, resource characteristics, and the dynamics of death for patients with a primary diagnosis of congestive heart failure.
N Y State J Med. 1989 Feb;89(2):60-3.
9
A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.
N Engl J Med. 1991 Aug 1;325(5):303-10. doi: 10.1056/NEJM199108013250502.
10
Efficient diagnosis of common complaints: a comparative study in the United States and England.
J Fam Pract. 1991 Jul;33(1):41-6.
Zotero 插件